Blood test clues could speed up ALS drug development

NCT ID NCT07334743

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to find biological markers in the blood that can help measure whether a potential ALS therapy is working. Researchers will collect tiny particles shed by brain cells from 30 ALS patients and 30 healthy volunteers. By comparing these particles, they hope to identify signals that could be used in future early-stage trials of a treatment called ENGRAILED1.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could identify blood-based biomarkers that make it easier and faster to test a new ALS therapy in early-stage trials.

What could go wrong

This is an observational study, not a treatment trial. It is small (60 people) and exploratory, so the biomarkers found may not prove useful in later trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hopital Fondation Adolphe de Rothschild

    RECRUITING

    Paris, 75019, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••